Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Milei Threatens Falkland Oil Firms With Sanctions 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
OpenAI Rejects Apple Trade Secret Theft Claims 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
INDIANAPOLIS, March 05, 2018 -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced that Derek Small, Assembly’s president and chief executive officer, will present at the Cowen Annual Healthcare Conference in Boston on Wednesday, March 14, 2018 at 10:00 a.m ET.
A live audio webcast of the presentation will be available at investor.assemblybio.com, and a replay will be available for approximately 30 days.
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. Assembly’s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. For more information, visit assemblybio.com.
Contacts
Assembly Biosciences, Inc.
Investors:
Lauren Glaser
(415) 521-3828
[email protected]
Media:
Barbara Lindheim
(212) 584-2276
[email protected]
